文献速递腹部技术与安全CTMR

肝硬化患者肝细胞癌检测:增强CT与细胞外对比剂MRI及钆塞酸二钠MRI的诊断性能比较

Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
PubMed 文献 · Eur Radiol · 2019-10-31

回顾性纳入277例肝硬化肝移植患者,以 explant 病理为参考,比较增强CT、细胞外对比剂MRI(EC-MRI)和钆塞酸二钠MRI(EOB-MRI)检测HCC的敏感度。EOB-MRI(含肝胆期)患者水平敏感度最高(95.2%),优于CT(86.3%)和EC-MRI(89.5%);病灶水平EC-MRI与动态EOB-MRI无差异,但添加肝胆期可提高检出。

要点

  • 患者水平敏感度:CT 86.3%、EC-MRI 89.5%、动态EOB-MRI 92.8%、完整EOB-MRI 95.2%,完整EOB-MRI显著优于CT和EC-MRI。
  • 病灶水平敏感度:CT 59.5%、EC-MRI 78.5%、动态EOB-MRI 69.7%、完整EOB-MRI 76.8%,各MRI组均显著优于CT。
  • 对于1-1.9 cm HCC,完整EOB-MRI敏感度67.3%,显著优于动态EOB-MRI的57.3%。

核心结论

  • EOB-MRI在患者水平HCC检出敏感度上优于CT和EC-MRI,在病灶水平敏感度上与EC-MRI相当。
  • 对于1-1.9 cm的HCC,MRI方法检出敏感度均优于CT。
  • 添加肝胆期图像可提高使用钆塞酸二钠时的HCC检出。

研究设计与样本

  • 回顾性纳入277例连续接受肝移植且移植前90天内接受影像检查的患者,以 explant 病理为参考标准。
  • 影像检查包括CT(n=100)、EC-MRI(n=77)和EOB-MRI(n=100),后者再分为动态EOB-MRI和完整EOB-MRI(动态+肝胆期)。
  • 三名放射科医生使用LI-RADSv2017算法回顾性分类≥1 cm的病灶,动态EOB-MRI额外评估添加肝胆期后的表现。

诊断标准与关键数值

  • 病理证实177例患者共265个HCC,平均大小2.1±1.4 cm。
  • 患者水平敏感度(合并读者数据):CT 86.3%、EC-MRI 89.5%、动态EOB-MRI 92.8%、完整EOB-MRI 95.2%;CT与动态EOB-MRI比较p=0.032,CT与完整EOB-MRI比较p=0.002,EC-MRI与完整EOB-MRI比较p=0.047。
  • 病灶水平敏感度:CT 59.5%、EC-MRI 78.5%、动态EOB-MRI 69.7%、完整EOB-MRI 76.8%;各MRI组与CT比较p范围0.001-0.04,EC-MRI与动态EOB-MRI比较p=0.949。
  • 1-1.9 cm HCC敏感度:CT 34.4%、EC-MRI 64.6%、动态EOB-MRI 57.3%、完整EOB-MRI 67.3%;各MRI组均显著优于CT(p≤0.01),完整EOB-MRI优于动态EOB-MRI(p=0.002)。
  • 采用LI-RADSv2017算法对≥1 cm病灶进行分类。

临床应用与阅片要点

  • 对于肝硬化患者HCC检出,MRI(尤其是完整EOB-MRI)患者水平敏感度高于CT。
  • 对于1-1.9 cm小HCC,MRI方法检出敏感度均优于CT。
  • 使用钆塞酸二钠时,添加肝胆期图像可提高HCC检出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast agents (EC-MRI) vs. MRI with gadoxetic acid (EOB-MRI) for HCC detection in patients with liver cirrhosis using liver explant as the reference. The additional value of hepatobiliary phase (HBP) post Gadoxetic acid was also assessed.

METHODS: Two-hundred seventy-seven consecutive patients who underwent liver transplantation over a 9 year period and imaging within 90 days of were retrospectively included. Imaging consisted in CT (n = 100), EC-MRI (n = 77) and EOB-MRI (n = 100), the latter subdivided into dynamic EOB-MRI and full EOB-MRI (dynamic+HBP). Three radiologists retrospectively categorized lesions ≥ 1 cm using the LI-RADSv2017 algorithm. Dynamic EOB-MRI was re-evaluated with the addition of HBP. Results were correlated with explant pathology.

RESULTS: Pathology demonstrated 265 HCCs (mean size 2.1 ± 1.4 cm) in 177 patients. Per-patient sensitivities were 86.3% for CT, 89.5% for EC-MRI, 92.8% for dynamic EOB-MRI and 95.2% for full EOB-MRI (pooled reader data), with a significant difference between CT and dynamic/full EOB-MRI (p = 0.032/0.002), and between EC-MRI and full EOB-MRI (p = 0.047). Per-lesion sensitivities for CT, EC-MRI, dynamic EOB-MRI and full EOB-MRI were 59.5%,78.5%,69.7% and 76.8%, respectively, with a significant difference between MRI groups and CT (p-range:0.001-0.04), and no difference between EC-MRI and dynamic EOB-MRI (p = 0.949). For HCCs 1-1.9 cm, sensitivities were 34.4%, 64.6%, 57.3% and 67.3%, respectively, with all MRI groups significantly superior to CT (p ≤ 0.01) and full EOB-MRI superior to dynamic EOB-MRI (p = 0.002).

CONCLUSIONS: EOB-MRI outperforms CT and EC-MRI for per-patient HCC detection sensitivity, and is equivalent to EC-MRI for per-lesion sensitivity. MRI methods outperform CT for detection of HCCs 1-1.9 cm.

KEY POINTS: • MRI is superior to CT for HCC detection in patients with liver cirrhosis. • EOB-MRI outperforms CT and MRI using extracellular contrast agents (EC-MRI) for per-patient HCC detection sensitivity, and is equivalent to EC-MRI for per-lesion sensitivity. • The addition of hepatobiliary phase images improves HCC detection when using gadoxetic acid.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Semaan S, Vietti Violi N, Lewis S, et al. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur Radiol. 2019. PMID: 31673837. doi:10.1007/s00330-019-06458-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。